Inpharma

Dexamethasone ineffective for bronchiolitis in infants
pp. 1-1(1)

State of plant-derived vaccines gives food for thought
pp. 2-2(1)

Booster dose of serogroup C meningococcal vaccine of value
pp. 3-3(1)

Health Canada shifts focus on drug regulation
pp. 3-3(1)

Interferon-α of variable value in melanoma
pp. 4-4(1)

News from ESH
pp. 4-4(1)

ACE inhibitors dominant for newly diagnosed T2DM
pp. 5-5(1)

LMWHs cost saving for DVT prevention
pp. 5-5(1)

Cinacalcet economically attractive in hyperthyroidism?
pp. 5-5(1)

Proactive screening for chlamydia not worth it in the UK
pp. 6-6(1)

ICER favours vinorelbine + cisplatin for NSCLC
pp. 6-6(1)

Sorafenib a worthy opponent for advanced renal cancer
pp. 6-6(1)

Factor Xa inhibitors the next direction in anticoagulation?
pp. 7-8(2)

A Vero cell-based seasonal influenza vaccine candidate may be promising for immunogenicity across three seasonal influenza strains
pp. 8-8(1)

A controlled-release (CR) formulation of interferon-α-2b [Locteron] appears promising for the treatment of chronic hepatitis C virus (HCV) infections
pp. 8-8(1)

OGX 011 plus docetaxel provides a greater benefit to patients with metastatic hormone-refractory prostate cancer than OGX 011 plus mitoxantrone
pp. 8-8(1)

Raltegravir gives new hope to HIV patients
pp. 9-10(2)

Olmesartan ± hydrochlorothiazide for hypertension
pp. 10-10(1)

News from IAS
pp. 11-11(1)

High-dose chemo + stem-cell rescue beats testicular cancer
pp. 11-11(1)

Carboplatin matches cisplatin for nasopharyngeal cancer
pp. 11-11(1)

Dexketoprofen noninferior to diclofenac for acute low back pain
pp. 12-12(1)

More aggressive atorvastatin therapy has an additional clinical benefit in elderly patients with stable coronary heart disease
pp. 12-12(1)

Calcium channel blockers reduce diabetes risk?
pp. 12-12(1)

Beclometasone clears the air for kids with asthma
pp. 12-12(1)

Extended-duration enoxaparin for VTE prophylaxis promising
pp. 13-13(1)

Medroxyprogesterone is an effective, fertility sparing treatment for endometrial cancer and atypical hyperplasia, but the recurrence rate is considerable
pp. 14-14(1)

Somatropin for HIV-associated adipose redistribution syndrome
pp. 14-14(1)

Among paediatric patients, budesonide inhaled suspension (BIS) recipients have a reduced risk of asthma-related hospitalisation recurrence
pp. 14-14(1)

Metronidazole for bacterial vaginosis lowers chlamydia risk
pp. 14-14(1)

A STAT3 polymorphism can be used to predict the response to interferon-α in patients with metastatic renal cell cancer
pp. 15-15(1)

Naproxen and paracetamol [acetaminophen] are comparable for the treatment of soft tissue injuries to the ankle in young people
pp. 15-15(1)

Film-forming terbinafine solution effective for skin delivery
pp. 15-15(1)

Adjuvant ketamine improves cancer pain and has an opioid-sparing effect in paediatric patients
pp. 15-15(1)

Propofol is superior to alfentanil for the prevention of movement responses during dilatation and curettage under general anaesthesia
pp. 15-15(1)

Avandia remains an option in the US
pp. 16-16(1)

GSK takes issue with Cochrane rosiglitazone review
pp. 16-16(1)

Minorities at greater risk of warfarin-related ICH
pp. 16-16(1)

Thiazolidinediones may increase risk of heart failure
pp. 17-17(1)

VICTOR analysis shows increased CV events with Vioxx
pp. 17-17(1)

Inhospital use of opioids increases the occurrence of postoperative paralytic ileus
pp. 17-17(1)

The US FDA has placed a clinical hold on an investigational gene therapy product for the treatment of active inflammatory arthritis
pp. 17-17(1)

Other EU regulatory news
pp. 18-18(1)

US product approvals
pp. 18-18(1)

EU product approvals
pp. 18-18(1)

US product launches
pp. 18-18(1)

Other US regulatory news
pp. 19-19(1)

Health Canada has granted expanded approval of lumiracoxib [Prexige; Novartis] for the treatment of acute and chronic osteoarthritis
pp. 19-19(1)

Novartis' nilotinib [Tasigna] has been approved in by Swissmedic, the Swiss health authority, for the treatment of chronic myeloid leukaemia
pp. 19-19(1)